RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53

Oncogene

Volumn 23, Issue 32, 2004, Pages 5476-5486

  Wotton, Sandy F ^a   Blyth, Karen ^a   Kilbey, Anna ^a   Jenkins, Alma ^a   Terry, Anne ^a   Bernardin Fried, Florence ^b   Friedman, Alan D ^b   Baxter, Euan W ^c   Neil, James C ^a   Cameron, Ewan R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

MEF; Oncogene; p53; RUNX1; TGF

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR RUNX1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE S PHASE; CELL DENSITY; CELL GROWTH; CONTACT INHIBITION; CONTROLLED STUDY; CYTOSKELETON; EMBRYO; EMBRYO CELL; FIBROBLAST; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH;

3T3 CELLS; ANIMALS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; FIBROBLASTS; MICE; PROTO-ONCOGENE PROTEINS; S PHASE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MAMMALIA;

EID: 3843099394     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207729     Document Type: Article

References (52)

1. Bae SC, Lee KS, Zhang YW and Ito Y. (2001). Intimate relationship between TGF-beta/BMP signaling and runt domain transcription factor, PEBP2/CBF. J. Bone Joint Surg. Am., 83-A (Suppl. 1), S48-S55.
2. Baxter EW, Blyth K, Cameron ER and Neil JC. (2001). Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice. J. Virol., 75, 9790-9798.
3. Bernardin F and Friedman AD. (2002). AML1 stimulates G1 to S progression via its transactivation domain. Oncogene, 21, 3247-3252.
4. Blyth K, Stewart M, Bell M, James C, Evan G, Neil JC and Cameron ER. (2000). Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice. Oncogene, 19, 773-782.
5. Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC and Stewart M. (2001). Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene, 20, 295-302.
6. Brubaker KD, Vessella RL, Brown LG and Corey E. (2003). Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate, 56, 13-22.
7. Cameron ER, Blyth K, Hanlon L, Kilbey A, Mackay N, Stewart M, Terry A, Vaillant F, Wotton S and Neil JC. (2003). The Runx genes as dominant oncogenes. Blood Cells Mol. Dis., 30, 194-200.
8. Chow M and Rubin H. (2000a). Clonal selection versus genetic instability as the driving force in neoplastic transformation. Cancer Res., 60, 6510-6518.
9. Chow M and Rubin H. (2000b). Coculturing diverse clonal populations prevents the early-stage neoplastic progression that occurs in the separate clones. Proc. Natl. Acad. Sci. USA, 97, 174-178.
10. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C and Piccolo S. (2003). Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell, 113, 301-314.
11. Dal Cin P, Atkins L, Ford C, Ariyanayagam S, Armstrong SA, George R, Cleary A and Morton CC. (2001). Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes Chromosomes Cancer, 30, 407-409.
12. Derynck R, Akhurst RJ and Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet., 29, 117-129.
13. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
14. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW and Nimer SD. (1995). The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene, 11, 2667-2674.
15. Frank RC, Sun X, Berguido FJ, Jakubowiak A and Nimer SD. (1999). The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene, 18, 1701-1710.
16. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K and Ito Y. (1999). Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J. Biol. Chem., 274, 31577-31582.
17. Harewood L, Robinson H, Harris R, Al Obaidi MJ, Jalali GR, Martineau M, Moorman AV, Sumption N, Richards S, Mitchell C and Harrison CJ. (2003). Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia, 17, 547-553.
18. Ito Y and Miyazono K. (2003). RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr. Opin. Genet. Dev., 13, 43-47.
19. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J and Nimer SD. (2000). Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J. Biol. Chem., 275, 40282-40287.
20. Ji C, Casinghino S, Chang DJ, Chen Y, Javed A, Ito Y, Hiebert SW, Lian JB, Stein GS, McCarthy TL and Centrella M. (1998). CBFa(AML/PEBP2)-related elements in the TGF-beta type I receptor promoter and expression with osteoblast differentiation. J. Cell. Biochem., 69, 353-363.
21. Kurokawa M, Tanaka T, Tanaka K, Ogawa S, Mitani K, Yazaki Y and Hirai H. (1996). Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene, 12, 883-892.
22. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM and Bae SC. (2000). Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluaripotent mesenchymal precursor cell line C2C12. Mol. Cell. Biol., 20, 8783-8792.
23. Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T, Shaughnessy Jr JD, Jenkins NA and Copeland NG. (1999). Leukaemia disease genes: large-scale cloning and pathway predictions. Nat. Genet., 23, 348-353.
24. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y. (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell, 109, 113-124.
25. Linggi B, Muller-Tidow C, van de LL, Hu M, Nip J, Serve H, Berdel WE, van der RB, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP and Hiebert SW. (2002). The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p 14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med., 8, 743-750.
26. Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI. (1995). A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res., 23, 1686-1690.
27. Lou J, Cao W, Bernardin F, Ayyanathan K, Rauscher III FJ and Friedman AD. (2000). Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene, 19, 2695-2703.
28. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ, Rauscher FJ and III. (1994). Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci. USA, 91, 4509-4513.
29. Meyers S, Lenny N and Hiebert SW. (1995). The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell. Biol., 15, 1974-1982.
30. Mikhail FM, Serry KA, Hatem N, Mourad ZI, Farawela HM, El Kaffash DM, Coignet L and Nucifora G. (2002). AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia, 16, 658-668.
31. Morgenstern JP and Land H. (1990). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18, 3587-3596.
32. Moustakas A and Stournaras C. (1999). Regulation of actin organisation by TGF-beta in H-ras-transformed fibroblasts. J. Cell Sci., 112 (Part 8), 1169-1179.
33. Nelson PJ and Daniel TO. (2002). Emerging targets: Molecular mechanisms of cell contact-mediated growth control. Kidney Int. Suppl., 61 (Suppl 1), 99-105.
34. Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM and Knuutila S. (2000). AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematologica, 85, 362-366.
35. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, Harada H and Downing JR. (1998). Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood, 91, 3134-3143.
36. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Dufios N, Garand R, Lai JL, Dastugue N, Macintyre E, Denis C, Bauters F, Kerckaert JP, Cosson A and Fenaux P. (2000). High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 96, 2862-2869.
37. Roberts AB and Wakefield LM. (2003). The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl. Acad. Sci. USA, 100, 8621-8623.
38. Sakamoto Y, Takeda Y, Takagi H, Tsuchiya T, Shoji A, Miyazaki K and Umeda M. (1999). Inhibition of focus formation of transformed cloned cells by contact with non-transformed BALB/c 3T3 A31-1-1 cells. Cancer Lett, 136, 159-165.
39. Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88, 593-602.
40. Siegel PM and Massague J. (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer, 3, 807-820.
41. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM and Gilliland DG. (1999). Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia (see comments). Nat. Genet., 23, 166-175.
42. Speck NA and Gilliland DG. (2002). Core-binding factors in haematopoiesis and leukaemia. Nat. Rev. Cancer, 2, 502-513.
43. Stewart M, Mackay N, Cameron ER and Neil JC. (2002). The common retroviral insertion locus Dsil maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/ Am12 gene. J. Virol., 76, 4364-4369.
44. Stewart M, Terry A, Hu M, O'Hara M, Blyth K, Baxter E, Cameron E, Onions DE and Neil JC. (1997). Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc. Natl. Acad. Sci. USA, 94, 8646-8651.
45. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR, Lenny N and Hiebert SW. (2000). Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J. Biol. Chem., 275, 3438-3445.
46. Sun L, Vitolo M and Passaniti A. (2001). Runt-related gene 2 in endothelial cells: inducible expression and specific regulation of cell migration and invasion. Cancer Res., 61, 4994-5001.
47. Vaillant F, Blyth K, Andrew L, Neil JC and Cameron ER. (2002). Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection. J. Immunol., 169, 2866-2874.
48. Vaillant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J and Stewart M. (1999). A full-length Cbfal gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene, 18, 7124-7134.
49. Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, Neil JC and Cameron ER. (2002). Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res., 62, 7181-7185.
50. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marin-Padilla M, Tenen DG, Speck NA and Zhang DE. (1997). Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet., 15, 303-306.
51. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C and Chung LW. (2002). Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J. Biol Chem., 277, 2468-2476.
52. Zhang YW, Yasui N, Ito K, Huang G, Fujii M, Hanai J, Nogami H, Ochi T, Miyazono K and Ito Y. (2000). A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc. Natl. Acad. Sci. USA, 97, 10549-10554.